FIG 1.

(A) ORR,^a (B) PFS,^b and (C) OS in patients with HER2-amplified and/or -overexpressed tumors by KRAS status. (D) Best percentage change in sum of target lesions in patients with HER2 amplification and/or overexpression by tumor group (n = 263); the horizontal line represents the 30% decrease in the sum of diameters of target lesions, from baseline. (E) ORR in patients with HER2-amplified and/or -overexpressed + KRAS wild-type tumors by tumor group (n = 202). ^aResponse was assessed by the investigator using RECIST v1.1. ^bData for patients without disease progression or death were censored at the date of the last tumor assessment (or, if no tumor assessments were performed, after the baseline visit, at the date of first treatment). Kaplan-Meier curves are for descriptive purposes only. Bar graph whiskers represent 95% CI. A/O, amplified and/or overexpressed; GYN, gynecologic; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; KRAS, Kirsten rat sarcoma viral oncogene homolog; NE, not estimable; NSCLC, non–small-cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TL, target lesion; UNK, unknown; WT, wild-type.